JP2020521784A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521784A5
JP2020521784A5 JP2019565921A JP2019565921A JP2020521784A5 JP 2020521784 A5 JP2020521784 A5 JP 2020521784A5 JP 2019565921 A JP2019565921 A JP 2019565921A JP 2019565921 A JP2019565921 A JP 2019565921A JP 2020521784 A5 JP2020521784 A5 JP 2020521784A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
group
orn
functional variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019565921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/064355 external-priority patent/WO2018220123A1/en
Publication of JP2020521784A publication Critical patent/JP2020521784A/ja
Publication of JP2020521784A5 publication Critical patent/JP2020521784A5/ja
Pending legal-status Critical Current

Links

JP2019565921A 2017-05-31 2018-05-31 長時間作用性ｇｉｐペプチド類似体 Pending JP2020521784A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17173628.3 2017-05-31
EP17173628 2017-05-31
PCT/EP2018/064355 WO2018220123A1 (en) 2017-05-31 2018-05-31 Long-acting gip peptide analogues

Publications (2)

Publication Number Publication Date
JP2020521784A JP2020521784A (ja) 2020-07-27
JP2020521784A5 true JP2020521784A5 (enExample) 2021-07-26

Family

ID=59021262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565921A Pending JP2020521784A (ja) 2017-05-31 2018-05-31 長時間作用性ｇｉｐペプチド類似体

Country Status (10)

Country Link
US (1) US11572399B2 (enExample)
EP (2) EP3630806B1 (enExample)
JP (1) JP2020521784A (enExample)
KR (1) KR102743887B1 (enExample)
CN (1) CN110691788B (enExample)
AU (1) AU2018276434B2 (enExample)
BR (1) BR112019025195A8 (enExample)
ES (1) ES2972848T3 (enExample)
PL (1) PL3630806T3 (enExample)
WO (1) WO2018220123A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3189072B1 (en) 2014-09-05 2018-07-18 University of Copenhagen Gip peptide analogues
WO2018220123A1 (en) 2017-05-31 2018-12-06 University Of Copenhagen Long-acting gip peptide analogues
RU2020136305A (ru) 2018-05-04 2022-05-05 Ново Нордиск А/С Производные gip и пути их применения
MX2021006505A (es) 2018-12-03 2021-10-01 Antag Therapeutics Aps Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
CN114761420B (zh) * 2019-12-03 2026-04-28 安泰博医药 优化的gip肽类似物
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
CZ297361B6 (cs) 1998-01-30 2006-11-15 Novo Nordisk A/S Injekcní stríkacka
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
KR20110043688A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
MX2011001031A (es) 2008-08-07 2011-04-26 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa.
CA2733006A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
EA020018B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Процессированные аналоги глюкозозависимого инсулинотропного полипептида
EP2528618A4 (en) * 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
CA2822617A1 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
WO2012168464A1 (en) * 2011-06-10 2012-12-13 Universität Bern Imaging and treatment of neuroendocrine tumors with glucose - dependent insulinotropic polypeptide or analogues or antagonists thereof
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
EP3189072B1 (en) 2014-09-05 2018-07-18 University of Copenhagen Gip peptide analogues
RU2716985C2 (ru) * 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2018069442A1 (en) * 2016-10-12 2018-04-19 University Of Copenhagen Peptide dual agonists of gipr and glp2r
EP3569248B1 (en) 2016-12-26 2023-12-06 Kao Corporation Gip inhibitors for improving cognitive function
JP7165495B2 (ja) 2016-12-26 2022-11-04 花王株式会社 運動調節機能向上剤
EP3560514A4 (en) 2016-12-26 2020-12-23 Kao Corporation Hypothermic drugs
WO2018220123A1 (en) 2017-05-31 2018-12-06 University Of Copenhagen Long-acting gip peptide analogues

Similar Documents

Publication Publication Date Title
JP7605747B2 (ja) 修飾されたｇｉｐペプチド類似体
JP2022509568A5 (enExample)
JP7658877B2 (ja) インクレチン類似体およびその使用
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
JP5986550B2 (ja) Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ
RU2485135C2 (ru) Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
DK2320923T3 (en) Truncated analogues of glucose-dependent insulinotropic polypeptide
JP2013518115A5 (enExample)
JP2011524420A5 (enExample)
JP2011502159A5 (enExample)
KR20150131213A (ko) 인슐린-인크레틴 접합체들
JP2014141500A (ja) グルカゴン／ｇｌｐ−１受容体コアゴニスト
HUE028072T2 (en) GIP-based agonists for the treatment of metabolic disease and obesity
KR20120123443A (ko) 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
EP2036923A1 (en) Improved derivates of amylin
JP2013505221A (ja) 長時間作用性ｙ２受容体アゴニスト
JP2016512213A5 (enExample)
JP2024521398A5 (enExample)
RU2752787C1 (ru) Пептидный аналог ацилированного оксинтомодулина
CN110691788B (zh) 长效gip肽类似物
JP2023505441A5 (enExample)
JP2007536214A (ja) Ｇｌｐ−１類似体
JP2023538871A5 (enExample)
RU2817673C2 (ru) Модифицированные аналоги GIP пептида